Immunic Q2 EPS $(0.54) Misses $(0.52) Estimate
Portfolio Pulse from Benzinga Newsdesk
Immunic (NASDAQ:IMUX) reported Q2 losses of $(0.54) per share, missing the analyst consensus estimate of $(0.52) by 3.85 percent. However, this is a 25 percent improvement over losses of $(0.72) per share from the same period last year.
August 04, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Immunic's Q2 earnings missed estimates, but showed a 25% YoY improvement. This mixed result may lead to uncertain short-term price movements.
Immunic's Q2 earnings missed the analyst consensus, which could negatively impact the stock. However, the YoY improvement in losses may be seen as a positive sign, potentially offsetting the negative impact. Therefore, the short-term price direction is uncertain.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100